Compare GROW & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GROW | HBIO |
|---|---|---|
| Founded | 1968 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 26.5M |
| IPO Year | 1995 | 2000 |
| Metric | GROW | HBIO |
|---|---|---|
| Price | $2.99 | $6.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 16.2K | 9.4K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | $23,850,609.00 | ★ $116,176,000.00 |
| Revenue This Year | N/A | $4.77 |
| Revenue Next Year | N/A | $8.55 |
| P/E Ratio | $11.30 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.23 | $0.38 |
| 52 Week High | $3.65 | $7.50 |
| Indicator | GROW | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.95 | 59.15 |
| Support Level | $2.89 | $5.91 |
| Resistance Level | $3.05 | $6.70 |
| Average True Range (ATR) | 0.09 | 0.23 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 76.19 | 95.14 |
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.